| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Axonyx Inc. > News item |
Axonyx: Phenserine effective in stabilizing brain volumes in Alzheimer's patients
By Lisa Kerner
Erie, Pa., April 19 - Axonyx Inc. said an analysis of study results suggests a stabilization of total brain volume and brain parenchymal fraction of mild-to-moderate Alzheimer's disease patients treated with Phenserine 10mg or 15mg twice daily for 26-weeks.
Phenserine is a selective inhibitor of acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine, important to memory and cognitive function.
Magnetic resonance imaging was used to examine the effects of Phenserine treatment on the brains of 16 Alzheimer's patients who were part of an earlier phase 3, 26-week, double blind, placebo-controlled clinical trial.
The primary aim of the sub-study was to investigate the potential effect of Phenserine treatment on the volume of different anatomical regions of the brain (brain parenchymal fraction, whole brain and the hippocampus), according to a company news release.
Axonyx said the mean percentage changes of brain volumes observed in the treated groups suggests a preservation of volume compared with the brain atrophy (loss of brain volume) seen in the placebo patient.
Alzheimer's disease is associated with an acceleration of brain atrophy that is generally greater than expected for non-demented persons of similar age.
The sub-study data will be presented in its entirety as a poster in Geneva at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy.
Axonyx is a New York City-based biopharmaceutical company specializing in proprietary pharmaceutical compounds for the treatment of central nervous system disorders.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.